Quality of life and symptom treatment response in postmenopausal women with advanced breast cancer (ABC) receiving Fulvestrant after progression on prior antiestrogen therapy

被引：0
|
作者：
Kalyadina, S. [1 ]
Novik, A. [2 ]
Ionova, T. [1 ]
机构：
[1] Multinat Ctr Qual Life Res, St Petersburg, Russia
[2] Pirogov Natl Med Surg Ctr, Moscow, Russia
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70666-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 195
页数：1
相关论文
共 50 条
  • [21] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [22] Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
    Jennifer Flemming
    Yolanda Madarnas
    Jacob A. Franek
    Breast Cancer Research and Treatment, 2009, 115
  • [23] Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
    Flemming, Jennifer
    Madarnas, Yolanda
    Franek, Jacob A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) : 255 - 268
  • [24] The impact of age on health related quality of life and symptom experience among postmenopausal women with breast cancer receiving adjuvant chemotherapy treatment
    Browall, M.
    Ahlberg, K.
    Persson, L.
    Karisson, P.
    Danielson, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 422 - 422
  • [25] Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group.
    Ingle, JN
    Rowland, KM
    Suman, VJ
    Mirchandani, D
    Bernath, AM
    Camoriano, JK
    Perez, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S38 - S38
  • [26] A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the
    Jiang, Zefei
    Zhang, Qingyuan
    Shao, Zhimin
    Shen, Kunwei
    Li, Li
    Feng, Jifeng
    Tong, Zhongseng
    Gu, Kangsheng
    Wang, Xiaojia
    Xu, Binghe
    Sun, Guofang
    Chen, Huifang
    Rukazenkov, Yuri
    CANCER RESEARCH, 2015, 75
  • [27] Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
    Loibl, Sibylle
    Turner, Nicholas C.
    Ro, Jungsil
    Cristofanilli, Massimo
    Iwata, Hiroji
    Im, Seock-Ah
    Masuda, Norikazu
    Loi, Sherene
    Andre, Fabrice
    Harbeck, Nadia
    Verma, Sunil
    Folkerd, Elizabeth
    Theall, Kathy Puyana
    Hoffman, Justin
    Zhang, Ke
    Bartlett, Cynthia Huang
    Dowsett, Mitchell
    ONCOLOGIST, 2017, 22 (09): : 1028 - 1038
  • [28] Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S57 - S58
  • [29] Previous Chemotherapy Influences the Symptom Experience and Quality of Life of Women With Breast Cancer Prior to Radiation Therapy
    Hofso, Kristin
    Miaskowski, Christine
    Bjordal, Kristin
    Cooper, Bruce A.
    Rustoen, Tone
    CANCER NURSING, 2012, 35 (03) : 167 - 177
  • [30] Symptom Clusters and Quality of Life in Women with Breast Cancer Receiving Adjuvant Chemotherapy
    Phligbua, Warunee
    Pongthavornkamol, Kanaungnit
    Knobf, Tish M.
    Junda, Tiraporn
    Viwatwongkasem, Chukiat
    Srimuninnimit, Vichien
    PACIFIC RIM INTERNATIONAL JOURNAL OF NURSING RESEARCH, 2013, 17 (03): : 249 - 267
12345